Jerusalem Post: Israeli drug for severe COVID reduces death by 70% – phase 2 trial

Jerusalem Post: Israeli drug for severe COVID reduces death by 70% – phase 2 trial. “Bonus BioGroup released new data this week showing that the 30-days survival rate of 50 severely ill hospitalized patients with oxygen saturation of 93% and below and diffuse pneumonia who received up to three doses of the company’s MesenCure treatment was 94% – meaning 47 out of 50 patients survived.”

Leave a Reply

%d bloggers like this: